2016
Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer
Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2016, 12: 314-322. PMID: 27720827, DOI: 10.1016/j.jtho.2016.09.122.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPneumonectomyPrognosisRetrospective StudiesSurvival RateTime FactorsConceptsNational Cancer Data BaseNeoadjuvant chemoradiationTiming of surgeryOverall survivalAdvanced non-small cell lung cancerNon-small cell lung cancerStage IIIA-N2 NSCLCStage IIIA NSCLCKaplan-Meier methodOverall survival rateSubset of patientsCell lung cancerLog-rank testMultivariate survival analysisProportional hazards modelIIIA NSCLCN2 NSCLCNeoadjuvant therapyTrimodality therapySurgical resectionClinical stageRetrospective studyLung cancerHazards modelSurvival rate
2015
Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database
Leuzzi G, Rocco G, Ruffini E, Sperduti I, Detterbeck F, Weder W, Venuta F, Van Raemdonck D, Thomas P, Facciolo F, Group E. Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database. Journal Of Thoracic And Cardiovascular Surgery 2015, 151: 47-57.e1. PMID: 26403869, DOI: 10.1016/j.jtcvs.2015.08.034.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAsiaChemotherapy, AdjuvantChildChi-Square DistributionDatabases, FactualDisease ProgressionDisease-Free SurvivalEuropeFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingNorth AmericaPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentRisk FactorsSocieties, MedicalThymectomyThymomaThymus NeoplasmsTime FactorsTreatment OutcomeTumor BurdenYoung AdultConceptsRelapse-free survivalAdvanced thymomaMultimodality therapyOverall survivalT classificationPropensity score-matched cohort studyMultivariate Cox proportional hazards modelPropensity score-matched analysisCox proportional hazards modelPathologic T classificationStage III thymomaThoracic Surgeons databaseSignificant survival advantageSpecific pathologic featuresStrong predictive factorProportional hazards modelInduction therapyAdjuvant therapyPT3 tumorsCohort studyIndependent predictorsPrognostic impactMultivariable analysisPathologic featuresPredictive factorsEvaluating the fate of patients who undergo resections of very large, node-negative lung cancers using the National Cancer DataBase
Liu J, Hancock JG, Moreno AC, Wang Z, Boffa DJ, Detterbeck FC, Kim AW. Evaluating the fate of patients who undergo resections of very large, node-negative lung cancers using the National Cancer DataBase. European Journal Of Cardio-Thoracic Surgery 2015, 49: 596-601. PMID: 25890936, DOI: 10.1093/ejcts/ezv139.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapy, AdjuvantDatabases, FactualFemaleFollow-Up StudiesHumansLung NeoplasmsLymph NodesMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPneumonectomyRetrospective StudiesSurvival AnalysisTreatment OutcomeTumor BurdenUnited StatesConceptsPostoperative radiation therapyNational Cancer DatabaseNeoadjuvant chemoradiation therapyAdjuvant chemoradiation therapyChemoradiation therapyAdjuvant chemotherapyOverall survivalSurgical therapyLung cancerCancer DatabaseNode-negative lung cancerImproved OS relativeLymph node involvementKaplan-Meier methodCell lung cancerCox regression modelFate of patientsLog-rank testDifferent treatment modalitiesOS relativeNode involvementMetastatic diseaseSurgical resectionLymph nodesOS rates
2014
Thymic carcinoma outcomes and prognosis: Results of an international analysis
Ahmad U, Yao X, Detterbeck F, Huang J, Antonicelli A, Filosso PL, Ruffini E, Travis W, Jones DR, Zhan Y, Lucchi M, Rimner A. Thymic carcinoma outcomes and prognosis: Results of an international analysis. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 95-101.e2. PMID: 25524678, DOI: 10.1016/j.jtcvs.2014.09.124.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingPractice Patterns, Physicians'Proportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSex FactorsThymectomyThymomaThyroid NeoplasmsTime FactorsTreatment OutcomeConceptsRecurrence-free survivalEarly Masaoka stageR0 resectionOverall survivalRadiation therapyMasaoka stageThymic carcinomaMale genderLonger recurrence-free survivalMedian overall survivalStage IV diseaseAdjuvant radiation therapyMasaoka stage IPreoperative radiation therapyPrimary outcome measureSquamous cell carcinomaPredominant histologic subtypeAdjuvant chemotherapyImproved OSInduction chemotherapyProlonged OSCumulative incidenceHistologic subtypeMultivariable analysisTreatment patternsOutcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases
Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, Travis W, Lucchi M, Rimner A, Antonicelli A, Guerrera F, Detterbeck F, Committee E. Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 103-109.e2. PMID: 25308116, DOI: 10.1016/j.jtcvs.2014.08.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overChemotherapy, AdjuvantDatabases, FactualFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingNeuroendocrine TumorsProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsThymectomyThymus NeoplasmsTime FactorsTreatment OutcomeYoung AdultConceptsInternational Thymic Malignancy Interest GroupMasaoka-Koga stageOverall survivalCompleteness of resectionPrimary neuroendocrine tumorThoracic Surgeons databasePrognostic factorsHistologic subtypeSurgeons databaseNeuroendocrine tumorsHigher biologic aggressivenessMasaoka-Koga stage ICommon histologic subtypeMedian overall survivalEuropean SocietyRetrospective multicenter studyKaplan-Meier methodStrong prognostic factorLog-rank testInduction therapyAdjuvant treatmentCumulative incidenceResection statusComplete resectionMulticenter study
2013
Impact of preoperative radiation on survival of patients with T3N0 >7-cm non–small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiology, and End Results database
Moreno AC, Morgensztern D, Yu JB, Boffa DJ, Decker RH, Detterbeck FC, Kim AW. Impact of preoperative radiation on survival of patients with T3N0 >7-cm non–small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiology, and End Results database. Journal Of Surgical Research 2013, 184: 10-18. PMID: 23583079, DOI: 10.1016/j.jss.2013.03.053.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellFemaleFollow-Up StudiesHumansIncidenceKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyPneumonectomyPreoperative CareProportional Hazards ModelsSEER ProgramYoung AdultConceptsNon-small cell lung cancerLung cancer-specific survivalEnd Results (SEER) databaseNeoadjuvant radiationSurvival of patientsCell lung cancerResults databaseLung cancerLarge non-small cell lung cancersFive-year overallCancer-specific survivalEffect of surgeryKaplan-Meier methodCox regression modelLog-rank testCombination of chemotherapyLong-term survivalAnatomic resectionPreoperative radiationWorse OSTherapeutic challengeLarge tumorsPneumonectomyLobectomyPatients
2011
An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non–small cell lung cancer
Kim AW, Boffa DJ, Wang Z, Detterbeck FC. An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non–small cell lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2011, 143: 55-63. PMID: 22056364, DOI: 10.1016/j.jtcvs.2011.09.002.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsNeoadjuvant TherapyPneumonectomyTime FactorsConceptsNeoadjuvant therapyPerioperative mortalityRight pneumonectomyLeft pneumonectomyNon-small cell lung cancerCumulative mortalityCell lung cancerSystematic PubMed searchFixed-effects modelPulmonary complicationsLung cancerCommon causePneumonectomyMortality differencesPubMed searchMortality figuresSystematic reviewMortalityTherapyOriginal articlesSearch strategyComplicationsCancerStudy
2009
Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer
Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ. Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer. CHEST Journal 2009, 135: 1588-1595. PMID: 19188545, DOI: 10.1378/chest.08-1430.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCisplatinConfidence IntervalsDeoxycytidineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelPneumonectomyPreoperative CareProbabilityRespiratory Function TestsRisk AssessmentSurvival AnalysisConceptsNon-small cell lung cancerCell lung cancerSurgical resectionLung cancerPulmonary toxicityResectable early stage non-small cell lung cancerEarly-stage non-small cell lung cancerRandomized phase 2 trialPulmonary function test resultsSecondary end pointsCombination of gemcitabinePhase 2 trialPulmonary function testsGemcitabine-based chemotherapyFunction test resultsTotal lung capacityEligible patientsNonplatinum regimensDyspnea scoreInterstitial pneumonitisPreoperative chemotherapyFunction testsSmoking statusClinical symptomsPreoperative setting
2008
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)
Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch DM, Limentani SA, Govindan R, Peng G, Monberg MJ, Obasaju CK, Socinski MA. Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Supportive Care In Cancer 2008, 17: 307-313. PMID: 18781341, DOI: 10.1007/s00520-008-0489-y.Peer-Reviewed Original ResearchConceptsLung Cancer Symptom ScaleNon-small cell lung cancerQuality of lifeCancer Symptom ScaleCell lung cancerNeoadjuvant therapyPostsurgical evaluationLung cancerSymptom ScaleEarly-stage non-small cell lung cancerStage non-small cell lung cancerClinical stage IECOG performance statusSubgroup of patientsModalities of treatmentSignificant survival gainStable QOLConclusionsMost patientsNeoadjuvant trialsAdjuvant approachPerformance statusPreoperative chemotherapyComplete resectionStable symptomsSurvival gainNeoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer
Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK. Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 37-45. PMID: 18166839, DOI: 10.1097/jto.0b013e31815e5d9a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCisplatinDeoxycytidineDrug Administration ScheduleFeasibility StudiesFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelSurvival AnalysisTime FactorsTreatment OutcomeConceptsEarly-stage non-small cell lung cancerNon-small cell lung cancerCell lung cancerGemcitabine 1000Day 1Neoadjuvant chemotherapyLung cancerResponse ratePathologic complete response rateRandomized phase II trialPhase III settingClinical response rateComplete response ratePerioperative mortality ratePrimary end pointComplete resection ratePhase II trialCarboplatin areaEligible patientsII trialPreoperative regimenResection rateSame regimenUnderwent surgeryMedian survival
2003
Changes in the treatment of Pancoast tumors
Detterbeck FC. Changes in the treatment of Pancoast tumors. The Annals Of Thoracic Surgery 2003, 75: 1990-1997. PMID: 12822662, DOI: 10.1016/s0003-4975(03)00134-6.Peer-Reviewed Original Research